A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy i… (NCT07424287) | Clinical Trial Compass
Not Yet RecruitingPhase 3
A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC
China236 participantsStarted 2026-03
Plain-language summary
This is a multicenter, randomized, open-label phase III study to determine the efficacy and safety of intravesical SHR-1501 combined with Bacillus Calmette Guerin (BCG) versus investigator-selected chemotherapy in patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC).
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Aged at least 18 years, gender is not limited;
✓. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2;
✓. Histologic confirmation of high-risk non-muscle invasive bladder cancer; BCG-unresponsive;
✓. Cystoscopy within 6 weeks before the randomization shows that the lesion has been completely removed; for T1 stage lesions, pathological results must show the presence of bladder muscle tissue;
✓. Not suitable for or unwilling to undergo radical cystectomy;
✓. Sufficient hematology and organ function.
Exclusion criteria
✕. Previous histopathological diagnosis was muscle-invasive, locally advanced or metastatic urothelial carcinoma (T2 or T3 or T4 or N+ or M+);
✕. Received surgery such as TURBT or radiotherapy for bladder lesions within 2 weeks before the randomization; Major surgery was performed within 28 days before randomization;
✕. Those who have previously received the following treatments and have not experienced disease recurrence or progression before enrolment: a) Intravesical infusion of cytotoxic chemotherapy or other drugs (such as oncolytic viruses), etc; b) Immune checkpoint inhibitors; c) Other investigatory drugs for the treatment of NMIBC;
✕. Those who have previously received immunostimulant therapy;
✕. Upper urinary tract tumor detected by CTU or MRU during screening period, urethral prostate tumor detected by cystoscopy, or other concomitant malignant tumors within 5 years before the first administration;